This is a routine CFO transition with an internal interim replacement already named, reducing near-term disruption risk. Monitor for the permanent CFO appointment announcement, which could signal strategic direction. No immediate trading catalyst from this filing alone.
PFE drugs
PFE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 18 $25.21entry
- T+1 · 5mo ago −0.52%α −0.20% · $25.08
- T+5 · 5mo ago −6.11%α −4.44% · $23.67
- T+20 · 4mo ago −0.28%α −0.81% · $25.14
- T+60 · 2mo ago +9.96%α +8.06% · $27.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pfizer announced that CFO Dave Denton will step down effective August 15, 2026 to pursue a consumer goods opportunity, with Senior VP Cecile Guegan appointed as Interim CFO effective August 16. The company explicitly states the departure is unrelated to financial or operating results. A comprehensive internal and external search for a permanent CFO is underway.
Key Facts
- CFO Dave Denton notified Pfizer on June 16, 2026 of his departure effective August 15, 2026 for a professional opportunity outside the pharmaceutical industry in consumer goods
- Cecile Guegan, SVP Finance, Global Biopharmaceutical Business, named Interim CFO effective August 16, 2026
- Departure stated as not related to the company's financial or operating results or any disagreements with accounting/reporting policies
- Pfizer will conduct a comprehensive internal and external search for a permanent CFO successor
Financial Impact
No financial figures disclosed in this filing; CFO transition with interim appointment, no immediate financial impact
Risk Factors
- Extended CFO vacancy could create leadership uncertainty if permanent search takes longer than expected
- Interim CFO may lack the external investor relations experience of the departing CFO, potentially affecting communication during the next earnings call
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000078003-26-000085 |
| Document: draftcfoannouncement061726.htm | 0000078003-26-000085 |
| Document: 0000078003-26-000085-index-headers.html | 0000078003-26-000085 |
| Document: 0000078003-26-000085-index.html | 0000078003-26-000085 |
| Document: 0000078003-26-000085.txt | 0000078003-26-000085 |
Track record
21 reports on PFE
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.86 −6.27% settles Feb 2
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.86 −3.80% settles Feb 1
- Oct 30, 202617d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.86 −5.90% settles Jan 29
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.86 −3.90% settles Jan 21
- Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.86 +7.73% ▲ +9.11% +12.15% vs SPY
- Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers